Pfizer Prospects Garner Mixed Sentiment From Analysts: ‘Finally, The Pivot Investors Have Been Waiting For’
Pfizer analysts from Goldman see a positive outlook on Padcev, Prevnar, and Vindaqel, but Nurtec and Oxbryta execution needs work.
Why Is Medical Device Maker Baxter Stock Trading Lower On Thursday?
Baxter reports Q1 adjusted EPS at $0.65, up 10% Y/Y, surpassing expectations. Sales hit $3.59 billion, with 2% growth on a reported basis.
Why Bausch Health Companies Shares Are Falling After Q1 Results
Bausch Health misses Q1 EPS estimates at 59 cents, despite a revenue increase of 11%.
Bayer’s Monsanto Scores Legal Victory as $185M Verdict Overturned
Bayer's Monsanto unit secures a significant legal victory as Washington state appeals court overturns $185 million verdict over chemical contamination. This highlights broader legal battles over PCBs and glyphosate's alleged cancer-causing effects.
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025 Formula, Stock Soars
Moderna reports Q1 loss, beating sales estimates amidst declining COVID-19 vaccine demand. Cost-saving measures drive optimism for investors. CEO Stéphane Bancel eyes strategic investments. Guidance reaffirms $4 billion sales target for 2024.
Why Is Nano-Cap Allarity Therapeutics Stock Trading Up On Thursday?
Allarity Therapeutics halts Phase 2 trial, citing compelling early results and plans for regulatory advancement. CEO Thomas Jensen affirms strategic shift. ALLR shares surge 38%.
Becton & Dickinson ‘Is Well On Its Way To Achieving 2025 Commitments,’ Analyst Optimistic On Outlook
BD reports Q2 sales of $5.04 billion, up 4.6% Y/Y. BD Medical, Life Sciences, and Interventional segments show growth. Guidance was raised for 2024 sales, and EPS was adjusted. William Blair rates BDX shares Outperform.
Cigna Crushes Q1 Estimates: Revenue Soars With Evernorth’s Explosive Growth
Cigna beats sales expectations with a 23% Y/Y increase to $57.26 billion, driven by Evernorth Health Services' growth and strong contributions from Cigna Healthcare. Explore financial insights and future guidance.
Demand Soars For Novo Nordisk’s Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition
The Danish pharmaceutical company is now shipping more introductory doses of Wegovy to the U.S., as it grapples with supply constraints and competition from Eli Lilly.
Federal Trade Commission Targets ‘Junk Patent Listings’ For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca
The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, and COPD medications. This initiative combats tactics hindering generic competition.